NASDAQ / LIVE COMPANY INTELLIGENCE

Fulgent Genetics, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERFLGT
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / FLGT COVERAGE

What’s moving Fulgent Genetics, Inc. now

Current reporting with the operating signal separated from the noise.

01
Fulgent Genetics, Inc. (FLGT) reports Q2 loss, misses revenue estimates

Fulgent Genetics, Inc. (FLGT) reports Q2 loss, misses revenue estimates

Investors are testing whether Fulgent Genetics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
02
Fulgent Genetics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Fulgent Genetics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Investors are testing whether Fulgent Genetics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
03
Fulgent Genetics, Inc. (NASDAQ:FLGT) Q4 2022 Earnings Call Transcript

Fulgent Genetics, Inc. (NASDAQ:FLGT) Q4 2022 Earnings Call Transcript

Investors are testing whether Fulgent Genetics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
04
INVESTOR NOTICE: Investors in Fulgent Genetics, Inc. with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – FLGT

INVESTOR NOTICE: Investors in Fulgent Genetics, Inc. with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – FLGT

The story matters when it changes Fulgent Genetics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
05
Fulgent Genetics, Inc. Investor Alert: Robbins LLP Informs Shareholders of Class Action Against Fulgent Genetics, Inc. (FLGT)

Fulgent Genetics, Inc. Investor Alert: Robbins LLP Informs Shareholders of Class Action Against Fulgent Genetics, Inc. (FLGT)

Investors are testing whether Fulgent Genetics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
06
Earnings Call Transcript

Fulgent Genetics, Inc. (FLGT) CEO Ming Hsieh on Q4 2020 Results

The story matters when it changes Fulgent Genetics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
PRIMARY DOCUMENTS / SEC EDGAR

Latest FLGT filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-07-30 · Period 2026-06-30SEC ↗10-QQuarterly financial reportFiled 2026-05-01 · Period 2026-03-31SEC ↗10-KAnnual financial reportFiled 2026-02-27 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-07-30 · Period 2026-07-30SEC ↗8-KMaterial company eventFiled 2026-06-02 · Period 2026-06-01SEC ↗8-KMaterial company eventFiled 2026-05-21 · Period 2026-05-21SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-03-31 · Period 2026-03-31SEC ↗4Official SEC filingFiled 2026-07-28 · Period 2026-07-26SEC ↗
EARNINGS / QUARTERLY TRACKER

Fulgent Genetics, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.